Search
Ascorbyl phosphate
go.drugbank.com/drugs/DB11352ApprovedInvestigationalThese salts are present in cosmetic products at concentrations ranging from 0.001 % to 3% [A27211]. … While ascorbyl phosphate salts provide a constant delivery of vitamin C into the skin, they also mediate an antioxidant action to act as a free radical scavenger and increases collagen production *in vitro
Lactitol
go.drugbank.com/drugs/DB12942Approved[A190918] It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). … Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose].
Categories: Compounds used in a research, industrial, or household settingErgotamine
go.drugbank.com/drugs/DB00696ApprovedA vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexPlozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigationalPlozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels. … Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference.
Voxelotor
go.drugbank.com/drugs/DB14975Approved[T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease.
Infliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalInfliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. … Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469].
Products: REMICADE 100MG PUL HER INF, REMICADE 100MG PUL Z H INFLevacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. … Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic IndexBexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigationalBexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. … [A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge.
Cefamandole
go.drugbank.com/drugs/DB01326ApprovedWithdrawnCefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate]. … It is no longer marketed in the United States.
Mepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnPharmacologically, it is a post-ganglionic parasympathetic inhibitor. … Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon.